Midatech Pharma PLC Publication of Annual Report (5637R)
June 30 2020 - 7:37AM
UK Regulatory
TIDMMTPH
RNS Number : 5637R
Midatech Pharma PLC
30 June 2020
30 June 2020
Midatech Pharma PLC
("Midatech" or the "Company")
Publication of Annual Report
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery
technology company focused on improving the bio-delivery and
bio-distribution of medicines announces that electronic copies of
its Annual Report and Accounts for the year ended 31 December 2019
are now available from the Company's investor relations website at
http://www.midatechpharma.com/ . Hard copies of the 2019 Annual
Report and Accounts are expected to be posted to shareholders
shortly.
For more information, please contact:
Midatech Pharma PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)1235 888300
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)
Turner Pope Investments (TPI) Limited (Joint Broker)
Andrew Thacker (Corporate Broking)
Tel: +44(0)20 3657 0050
IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk
Edison Group (US Investor Relations)
Joseph Green/ Laine Yonker
Tel: (646) 653-7030/ 7035
jgreen@edisongroup.com/lyonker@edisongroup.com
About Midatech Pharma PLC
Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ:
MTP) is an R&D company focused on 'Making Medicines Better' by
improving delivery of drugs in the body. The Company combines
existing medications with its proprietary and innovative drug
delivery technologies to provide compelling oncology and rare
disease products that have the potential to powerfully impact the
lives of patients undergoing treatment for life threatening
diseases.
The Company has developed three in-house technology platforms,
each with its own unique mechanism to improve delivery of
medications to sites of disease. All of the Company's technologies
have successfully entered human use in the clinic, providing
important validation of the potential for each platform:
-- Q-Sphera(TM) platform: a disruptive micro-technology used for sustained release to prolong
and control the release of therapeutics over an extended period of time (from weeks to months).
-- MidaSolve(TM) platform: an innovative nano-technology used to dissolve insoluble drugs so
that they can be administered in liquid form directly and locally into tumours.
-- MidaCore(TM) platform: a leading edge nano-technology used for targeting medications to sites
of disease.
By improving biodelivery and biodistribution of approved
existing molecules, Midatech's unique R&D has the potential to
make medicines better, lower technical risks, accelerate regulatory
approval and route to market, and provide newly patentable
products. The platform nature of the technologies allows the
potential to develop multiple drug assets rather than being reliant
on a limited number of programmes.
Midatech's headquarters and R&D facility is in Cardiff, UK.
For more information please visit www.midatechpharma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACSFZGFVZGDGGZM
(END) Dow Jones Newswires
June 30, 2020 08:37 ET (12:37 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2024 to May 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From May 2023 to May 2024